Cagrilintide

Cagrilintide is a long-acting synthetic analogue of the hormone amylin, a peptide naturally co-secreted with insulin that plays an important role in satiety signalling and energy balance. Interest in cagrilintide has grown as researchers explore metabolic pathways beyond incretin-based therapies.

Unlike GLP-1 receptor agonists such as semaglutide, cagrilintide primarily acts on amylin receptors (AMYR) and the calcitonin receptor complex. These signalling pathways influence appetite regulation, gastric emptying, and post-meal metabolic responses.

Because amylin signalling complements incretin pathways, cagrilintide has become an important compound in metabolic research exploring how multiple hormonal systems interact to regulate hunger and long-term bodyweight balance.

Amylin Receptor Activation: Cagrilintide mimics the satiation hormone amylin, enhancing central satiety signals that help regulate appetite and feeding behaviour.

Gastric Emptying Regulation: Amylin signalling influences the rate at which food leaves the stomach, contributing to prolonged fullness and metabolic stability after meals.

Complementary Metabolic Pathway: Because it operates through amylin receptors rather than incretin receptors, cagrilintide represents a distinct signalling mechanism within metabolic research.

In controlled clinical studies, cagrilintide monotherapy has demonstrated dose-dependent weight reduction in metabolic research models. Early-stage trials reported reductions approaching 10–15% bodyweight over approximately 26–32 weeks under controlled conditions.

Researchers have also investigated cagrilintide in combination with GLP-1 receptor agonists, particularly semaglutide. This dual-pathway approach activates both incretin and amylin signalling systems and forms the basis of the investigational CagriSema combination therapy.

Blended peptide formulations based on this pairing are explored in combination-pathway research and can be found within our CagriSema blend.

Semaglutide: GLP-1 pathway activation (~14–15% reduction in clinical studies)

Tirzepatide: Dual incretin activation (GIP + GLP-1)

Retatrutide: Triple agonist signalling (GLP-1 / GIP / glucagon)

Cagrilintide: Amylin receptor pathway influencing satiety and metabolic regulation

Rather than replacing incretin-based therapies, cagrilintide represents a complementary signalling pathway that may enhance metabolic regulation when combined with GLP-1 compounds.

Satiation Signalling Studies: Investigation of central appetite control pathways.

Combination Metabolic Research: Dual-pathway studies combining amylin and incretin signalling.

Postprandial Metabolism: Research examining gastric emptying and glucose response following meals.

Energy Intake Regulation: Models studying appetite behaviour and feeding responses.

*Weight reduction figures reference published clinical research conducted under controlled study conditions.